Immune Control Despite Protracted Lymphopenia After Chemoradiation in an Elite Controller

Area of Science:

• Immunology
• Oncology
• Virology

Background:

• Elite controllers represent a unique cohort of human immunodeficiency virus-1 (HIV-1) positive individuals.
• These individuals naturally maintain undetectable viral loads without antiretroviral therapy.
• Understanding their immune mechanisms is crucial for HIV-1 cure research.

Purpose of the Study:

• To report on an elite controller diagnosed with extensive-stage small cell lung cancer (SCLC).
• To describe the viral load control and immune response in this patient during cancer treatment.
• To highlight the interplay between HIV-1 control and cancer-induced immune modulation.

Main Methods:

• Case report of an elite controller with SCLC.
• Monitoring of HIV-1 viral load and CD4+ T-cell counts.
• Assessment of treatment-related side effects, specifically lymphopenia.

Main Results:

• The patient maintained an undetectable HIV-1 viral load (<20 copies/mL) throughout the study period.
• Extensive-stage SCLC diagnosis and subsequent treatment were confirmed.
• Severe treatment-related lymphopenia developed, yet HIV-1 viral suppression persisted.

Conclusions:

• Elite controller status can be maintained even in the presence of significant comorbidities like advanced SCLC.
• The immune system in elite controllers may possess robust mechanisms to control HIV-1 replication despite profound immune stress.
• This case underscores the resilience of HIV-1 elite control and warrants further investigation into underlying mechanisms.